JP2012524075A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012524075A5 JP2012524075A5 JP2012505977A JP2012505977A JP2012524075A5 JP 2012524075 A5 JP2012524075 A5 JP 2012524075A5 JP 2012505977 A JP2012505977 A JP 2012505977A JP 2012505977 A JP2012505977 A JP 2012505977A JP 2012524075 A5 JP2012524075 A5 JP 2012524075A5
- Authority
- JP
- Japan
- Prior art keywords
- immunotherapy
- combination
- antigen
- composition
- individual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 50
- 238000009169 immunotherapy Methods 0.000 claims 33
- 239000000427 antigen Substances 0.000 claims 27
- 102000036639 antigens Human genes 0.000 claims 27
- 108091007433 antigens Proteins 0.000 claims 27
- 230000001024 immunotherapeutic effect Effects 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 201000011510 cancer Diseases 0.000 claims 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 12
- 150000007523 nucleic acids Chemical group 0.000 claims 12
- 230000002163 immunogen Effects 0.000 claims 11
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 9
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 9
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims 6
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 6
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 5
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 5
- 241000700662 Fowlpox virus Species 0.000 claims 4
- 241000700618 Vaccinia virus Species 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 108010084313 CD58 Antigens Proteins 0.000 claims 2
- 102000006108 VHL Human genes 0.000 claims 2
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 2
- 101150046474 Vhl gene Proteins 0.000 claims 2
- 102000001307 androgen receptors Human genes 0.000 claims 2
- 108010080146 androgen receptors Proteins 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 244000052769 pathogen Species 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 238000005215 recombination Methods 0.000 claims 2
- 230000006798 recombination Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 208000007089 vaccinia Diseases 0.000 claims 2
- SNKUSVNHTCUELQ-UHFFFAOYSA-N 2-[[4-amino-2-[[2-[[2-[2-[[2-[[2-[[2-[[2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]propanoylamino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoic aci Chemical compound CC(C)CC(C(O)=O)NC(=O)C(CC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(C)NC(=O)CNC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(N)CC1=CC=C(O)C=C1 SNKUSVNHTCUELQ-UHFFFAOYSA-N 0.000 claims 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 claims 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 claims 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 claims 1
- 102100036526 Anoctamin-7 Human genes 0.000 claims 1
- 108010077333 CAP1-6D Proteins 0.000 claims 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 1
- 108700037122 EWS-FLI fusion Proteins 0.000 claims 1
- 101710147220 Ent-copalyl diphosphate synthase, chloroplastic Proteins 0.000 claims 1
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 108010034145 Helminth Proteins Proteins 0.000 claims 1
- 101000928370 Homo sapiens Anoctamin-7 Proteins 0.000 claims 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 241000578472 Human endogenous retrovirus H Species 0.000 claims 1
- 241000192019 Human endogenous retrovirus K Species 0.000 claims 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 claims 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims 1
- 102000003735 Mesothelin Human genes 0.000 claims 1
- 108090000015 Mesothelin Proteins 0.000 claims 1
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 claims 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 108010008707 Mucin-1 Proteins 0.000 claims 1
- 102100023123 Mucin-16 Human genes 0.000 claims 1
- 102100034263 Mucin-2 Human genes 0.000 claims 1
- 108010008705 Mucin-2 Proteins 0.000 claims 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims 1
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 claims 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 1
- 102000018471 Proto-Oncogene Proteins B-raf Human genes 0.000 claims 1
- 108010091528 Proto-Oncogene Proteins B-raf Proteins 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 claims 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 claims 1
- 102100030306 TBC1 domain family member 9 Human genes 0.000 claims 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 claims 1
- 102000018252 Tumor Protein p73 Human genes 0.000 claims 1
- 108010091356 Tumor Protein p73 Proteins 0.000 claims 1
- 102100039094 Tyrosinase Human genes 0.000 claims 1
- 108060008724 Tyrosinase Proteins 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 244000078703 ectoparasite Species 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 244000000013 helminth Species 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- ONCZDRURRATYFI-QTCHDTBASA-N methyl (2z)-2-methoxyimino-2-[2-[[(e)-1-[3-(trifluoromethyl)phenyl]ethylideneamino]oxymethyl]phenyl]acetate Chemical compound CO\N=C(/C(=O)OC)C1=CC=CC=C1CO\N=C(/C)C1=CC=CC(C(F)(F)F)=C1 ONCZDRURRATYFI-QTCHDTBASA-N 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 108091008819 oncoproteins Proteins 0.000 claims 1
- 102000027450 oncoproteins Human genes 0.000 claims 1
- 230000003071 parasitic effect Effects 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 208000015768 polyposis Diseases 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 102000016914 ras Proteins Human genes 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 101150047061 tag-72 gene Proteins 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17053009P | 2009-04-17 | 2009-04-17 | |
| US61/170,530 | 2009-04-17 | ||
| PCT/US2010/031460 WO2010121180A1 (en) | 2009-04-17 | 2010-04-16 | Combination immunotherapy compositions against cancer and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014240182A Division JP2015044857A (ja) | 2009-04-17 | 2014-11-27 | 癌に対する併用免疫療法組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012524075A JP2012524075A (ja) | 2012-10-11 |
| JP2012524075A5 true JP2012524075A5 (cg-RX-API-DMAC7.html) | 2013-06-13 |
| JP5759980B2 JP5759980B2 (ja) | 2015-08-05 |
Family
ID=42237003
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012505977A Active JP5759980B2 (ja) | 2009-04-17 | 2010-04-16 | 癌および感染症に対する免疫療法組成物の組み合わせ |
| JP2014240182A Withdrawn JP2015044857A (ja) | 2009-04-17 | 2014-11-27 | 癌に対する併用免疫療法組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014240182A Withdrawn JP2015044857A (ja) | 2009-04-17 | 2014-11-27 | 癌に対する併用免疫療法組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US10383924B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2419126B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5759980B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR101781966B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102458458B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010236206B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2759013C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2660597T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2011010977A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010121180A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG171577A1 (en) | 2007-02-02 | 2011-06-29 | Globeimmune Inc | Methods for producing yeast-based vaccines |
| KR20100015661A (ko) | 2007-03-19 | 2010-02-12 | 글로브이뮨 | 암의 표적 치료법의 돌연변이성 이탈의 표적 절제를 위한 조성물 및 방법 |
| EP2170384B1 (en) | 2007-07-02 | 2016-04-13 | Etubics Corporation | Methods and compositions for producing an adenovirus vector for use with multiple vaccinations |
| ES2660597T3 (es) | 2009-04-17 | 2018-03-23 | Globeimmune, Inc. | Composiciones inmunoterápicas de combinación contra el cáncer y métodos |
| CA2774326C (en) | 2009-09-14 | 2023-11-07 | Donald Bellgrau | Modulation of yeast-based immunotherapy products and responses |
| MA34956B1 (fr) | 2011-02-12 | 2014-03-01 | Globeimmune Inc | Therapeutique a base de levure pour infection chronique par l'hepatite b |
| BR112013023456B1 (pt) * | 2011-03-17 | 2020-11-17 | Globeimmune, Inc. | composições imunoterapêuticas de levedura brachyury, e seus usos |
| EP2720716B1 (en) | 2011-06-14 | 2018-03-21 | Globeimmune, Inc. | Immunotherapeutic compositions for the treatment or prevention of hepatitis delta virus infection |
| JP6122007B2 (ja) | 2011-08-17 | 2017-04-26 | グローブイミューン，インコーポレイテッド | 酵母−ｍｕｃ１免疫療法用組成物およびその使用 |
| PL2591798T3 (pl) | 2011-11-09 | 2015-04-30 | Werner Lubitz | Szczepionka do zastosowania w immunoterapii nowotworów |
| US20150079027A1 (en) * | 2012-03-27 | 2015-03-19 | Dendritherapeutics, Inc. | Antitumor protocol |
| US9653272B2 (en) | 2012-06-26 | 2017-05-16 | Biodesix, Inc. | Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies |
| WO2014031178A1 (en) | 2012-08-24 | 2014-02-27 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
| WO2014043518A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use |
| WO2014043535A1 (en) * | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions for the treatment of cancer |
| GB201217868D0 (en) * | 2012-10-05 | 2012-11-21 | Isis Innovation | Staphyolococcus aureus antigens |
| KR20150132867A (ko) | 2013-03-19 | 2015-11-26 | 글로브이뮨 | 척색종에 대한 효모-기반의 면역치료 |
| WO2014160747A2 (en) | 2013-03-26 | 2014-10-02 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection |
| KR101502680B1 (ko) * | 2013-04-01 | 2015-03-17 | 중앙대학교 산학협력단 | 난소과립종양세포 진단용 펩타이드 및 이의 용도 |
| US10226522B2 (en) | 2013-08-30 | 2019-03-12 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of tuberculosis |
| WO2015123532A1 (en) * | 2014-02-16 | 2015-08-20 | Globeimmune, Inc. | Ras g12r immunotherapy for ras mutation-positive cancers |
| CN106456677B (zh) | 2014-04-11 | 2025-06-03 | 全球免疫股份有限公司 | 基于酵母的免疫疗法和i型干扰素敏感性 |
| US9753036B2 (en) * | 2014-04-29 | 2017-09-05 | Edp Biotech Corporation | Methods and compositions for screening and detecting biomarkers |
| JP2018502922A (ja) | 2015-01-09 | 2018-02-01 | イーチュービクス コーポレイション | エボラウイルスワクチン接種のための方法および組成物 |
| CN113456812B (zh) | 2015-01-09 | 2024-08-20 | 埃图比克斯公司 | 用于联合免疫治疗的方法和组合物 |
| US11149087B2 (en) | 2015-04-20 | 2021-10-19 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| IL256869B (en) | 2015-07-31 | 2022-07-01 | Bavarian Nordic As | Promoters for enhancing expression in poxvirus |
| US11065313B2 (en) | 2015-08-03 | 2021-07-20 | Globeimmune, Inc. | Modified yeast-brachyury immunotherapeutic compositions |
| EP3195878A1 (en) | 2016-01-22 | 2017-07-26 | Werner Lubitz | Bacterial ghosts for the treatment of cancer |
| JP2019512020A (ja) | 2016-02-12 | 2019-05-09 | マディソン ヴァクシーンズ インコーポレイテッド | がんの治療 |
| JP2019513021A (ja) | 2016-03-24 | 2019-05-23 | ナントセル，インコーポレイテッド | ネオエピトープ提示のための配列の配置および配列 |
| US11273170B2 (en) * | 2016-07-25 | 2022-03-15 | Ascend Biopharmaceuticals Ltd | Methods of treating cancer |
| AU2018258119B2 (en) | 2017-04-24 | 2021-04-01 | Nantcell, Inc. | Targeted neoepitope vectors and methods therefor |
| US10960071B2 (en) | 2017-08-07 | 2021-03-30 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
| KR20250056192A (ko) * | 2017-08-07 | 2025-04-25 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 안전한 세포 치료제를 생성하기 위한 플랫폼 |
| AU2018320417B2 (en) * | 2017-08-24 | 2024-11-14 | Bavarian Nordic A/S | Combination therapy for treating cancer with an intravenous administration of a recombinant MVA and an antibody |
| DE102017012109A1 (de) * | 2017-12-27 | 2019-06-27 | Martin-Luther-Universität Halle-Wittenberg | Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis |
| CN119818663A (zh) | 2018-05-15 | 2025-04-15 | 全球免疫公司 | 用于诱导细胞免疫应答的重组酵母裂解物 |
| US20210268087A1 (en) * | 2018-07-22 | 2021-09-02 | Health Research, Inc. | Major histocompatibility complex class ii-expressing cancer cell vaccine and methods of use for producing integrated immune responses |
| CN115397395A (zh) * | 2020-02-07 | 2022-11-25 | 加利福尼亚大学董事会 | 生物工程去核细胞的方法和用途 |
| US20210284716A1 (en) | 2020-03-11 | 2021-09-16 | Immunitybio, Inc. | ACE2-Fc Trap |
| US11857620B2 (en) | 2020-03-11 | 2024-01-02 | Immunitybio, Inc. | Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus |
| US12285480B2 (en) | 2020-03-11 | 2025-04-29 | Nantcell, Inc. | Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses |
| IL297335A (en) * | 2020-04-14 | 2022-12-01 | Univ California | Corona virus vaccine compounds |
| EP3957322A1 (en) * | 2020-08-19 | 2022-02-23 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Recombinant poxviridae vector expressing co-stimulatory molecules |
| CN113244273A (zh) * | 2021-03-16 | 2021-08-13 | 广州中科蓝华生物科技有限公司 | 疟原虫在制备联合放射疗法用于抗肿瘤的制剂中的应用 |
| WO2025207938A1 (en) * | 2024-03-29 | 2025-10-02 | University Of Washington | Nucleic acid vaccines against coccidioidomycosis |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1038392A (en) | 1912-04-17 | 1912-09-10 | Edmund P Kohn | Safety-catch for jewelry. |
| FR2486400B1 (fr) | 1980-07-09 | 1986-05-30 | Univablot | Medicaments a base de levures ou de leurs extraits insolubles |
| NZ199722A (en) | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
| US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| US4514506A (en) | 1982-02-23 | 1985-04-30 | The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services | Method for the identification and purification of human lung tumor-associated antigens (hLTAA) and clinical detection and determination of these antigens |
| US4775622A (en) | 1982-03-08 | 1988-10-04 | Genentech, Inc. | Expression, processing and secretion of heterologous protein by yeast |
| US5310654A (en) | 1985-07-31 | 1994-05-10 | The Board Of Trustees Of The Leland Stanford Junior University | Method for determining virulence of Yersinia |
| US5234830A (en) | 1988-02-03 | 1993-08-10 | Suntory Limited | DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region |
| US20060121011A1 (en) * | 1988-03-21 | 2006-06-08 | Jolly Douglas J | Combination gene delivery vehicles |
| US5093258A (en) | 1988-08-26 | 1992-03-03 | Therion Biologics Corporation | Recombinant fowlpox virus and recombination vector |
| IL95019A0 (en) | 1989-08-09 | 1991-06-10 | Mycogen Corp | Process for encapsulation of biologicals |
| US5554512A (en) | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
| US5413914A (en) | 1993-07-07 | 1995-05-09 | The Regents Of The University Of Colorado | Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases |
| US5830463A (en) | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
| US5648226A (en) | 1993-07-22 | 1997-07-15 | Ludwig Institute For Cancer Research | Isolated peptides derived from tumor rejection antigens, and their use |
| AU702517B2 (en) | 1993-08-06 | 1999-02-25 | Epimmune, Inc. | Cloning and characterization of the complete MAGE-1 gene |
| US5550214A (en) | 1994-02-10 | 1996-08-27 | Brigham And Women's Hospital | Isolated antigenic oncogene peptide fragments and uses |
| US5747282A (en) | 1994-08-12 | 1998-05-05 | Myraid Genetics, Inc. | 17Q-linked breast and ovarian cancer susceptibility gene |
| EP1016418B1 (en) | 1994-10-03 | 2009-12-30 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Host cell comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule |
| US6045802A (en) | 1994-10-03 | 2000-04-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule |
| US5840839A (en) | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
| US5858378A (en) | 1996-05-02 | 1999-01-12 | Galagen, Inc. | Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen |
| US6969609B1 (en) | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
| DE69837896T2 (de) | 1997-10-10 | 2008-02-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Peptidagonisten von karzinoembryonalem Antigen (CEA) |
| US20070048860A1 (en) | 1997-10-10 | 2007-03-01 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Carcinoembryonic antigen (CEA) peptides |
| ATE361988T1 (de) * | 1998-12-09 | 2007-06-15 | Us Gov Health & Human Serv | Recombinanter vector, welcher mehrere kostimulatorische moleküle exprimiert und dessen verwenden |
| US20020044948A1 (en) | 2000-03-15 | 2002-04-18 | Samir Khleif | Methods and compositions for co-stimulation of immunological responses to peptide antigens |
| AU1951001A (en) | 2000-04-06 | 2001-09-17 | Panacea Pharm Llc | Microbial delivery system |
| AU2002225681A1 (en) | 2000-11-15 | 2002-05-27 | Globe Immune, Inc. | Yeast-dentritic cell vaccines and uses thereof |
| CN1938044B (zh) | 2002-12-16 | 2011-12-28 | 全球免疫股份有限公司 | 用于免疫治疗的基于酵母的疫苗 |
| US7439042B2 (en) | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| CN1635118A (zh) * | 2003-12-29 | 2005-07-06 | 吉林大学第一医院 | 人癌胚抗原肽表位基因编码序列串联体的合成及表位疫苗 |
| CA2558382A1 (en) * | 2004-03-02 | 2005-09-15 | Tsuneya Ohno | Methods and compositions for hybrid cell vaccines for the treatment and prevention of cancer |
| JP2008516610A (ja) * | 2004-10-18 | 2008-05-22 | グローブイミューン，インコーポレイテッド | 酵母を用いた慢性ｃ型肝炎感染の治療 |
| WO2007008780A2 (en) | 2005-07-11 | 2007-01-18 | Globeimmune, Inc. | Compositions and methods for eliciting an immune response to escape mutants of targeted therapies |
| US20070172503A1 (en) | 2005-12-13 | 2007-07-26 | Mycologics,Inc. | Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines |
| KR101492524B1 (ko) | 2006-02-02 | 2015-02-12 | 글로브이뮨 | 면역 반응 유도를 위한 효모-기반 백신 |
| MX2008012392A (es) | 2006-03-27 | 2008-12-17 | Globeimmune Inc | Mutacion de ras, y composiciones y metodos relacionados con la misma. |
| WO2008019366A2 (en) | 2006-08-07 | 2008-02-14 | Ludwig Institute For Cancer Research | Methods and compositions for increased priming of t-cells through cross-presentation of exogenous antigens |
| SG171577A1 (en) | 2007-02-02 | 2011-06-29 | Globeimmune Inc | Methods for producing yeast-based vaccines |
| KR20100015661A (ko) | 2007-03-19 | 2010-02-12 | 글로브이뮨 | 암의 표적 치료법의 돌연변이성 이탈의 표적 절제를 위한 조성물 및 방법 |
| WO2010033841A1 (en) | 2008-09-19 | 2010-03-25 | Globeimmune, Inc. | Immunotherapy for chronic hepatitis c virus infection |
| WO2010065626A1 (en) | 2008-12-02 | 2010-06-10 | Globeimmune, Inc. | Genotyping tools, methods and kits |
| ES2660597T3 (es) | 2009-04-17 | 2018-03-23 | Globeimmune, Inc. | Composiciones inmunoterápicas de combinación contra el cáncer y métodos |
| CA2774326C (en) | 2009-09-14 | 2023-11-07 | Donald Bellgrau | Modulation of yeast-based immunotherapy products and responses |
| US20130121964A1 (en) | 2010-03-14 | 2013-05-16 | Globeimmune, Inc. | Pharmacogenomic and Response-Guided Treatment of Infectious Disease Using Yeast-Based Immunotherapy |
| WO2012019127A2 (en) | 2010-08-05 | 2012-02-09 | The Regents Of The University Of Colorado | Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases |
-
2010
- 2010-04-16 ES ES10715632.5T patent/ES2660597T3/es active Active
- 2010-04-16 JP JP2012505977A patent/JP5759980B2/ja active Active
- 2010-04-16 MX MX2011010977A patent/MX2011010977A/es active IP Right Grant
- 2010-04-16 KR KR1020117027319A patent/KR101781966B1/ko active Active
- 2010-04-16 KR KR1020177026393A patent/KR102019728B1/ko active Active
- 2010-04-16 CA CA2759013A patent/CA2759013C/en active Active
- 2010-04-16 EP EP10715632.5A patent/EP2419126B1/en active Active
- 2010-04-16 US US13/264,846 patent/US10383924B2/en active Active
- 2010-04-16 CN CN201080026166.0A patent/CN102458458B/zh active Active
- 2010-04-16 AU AU2010236206A patent/AU2010236206B2/en active Active
- 2010-04-16 EP EP17203871.3A patent/EP3320915A1/en active Pending
- 2010-04-16 WO PCT/US2010/031460 patent/WO2010121180A1/en not_active Ceased
-
2014
- 2014-11-27 JP JP2014240182A patent/JP2015044857A/ja not_active Withdrawn
-
2019
- 2019-07-01 US US16/458,726 patent/US10874729B2/en active Active
-
2020
- 2020-11-18 US US16/951,739 patent/US11596675B2/en active Active
- 2020-12-22 US US17/130,551 patent/US11590216B2/en active Active
-
2023
- 2023-01-24 US US18/158,800 patent/US12076382B2/en active Active
-
2024
- 2024-07-05 US US18/764,645 patent/US20240350604A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012524075A5 (cg-RX-API-DMAC7.html) | ||
| JP2014509595A5 (cg-RX-API-DMAC7.html) | ||
| Vergati et al. | Strategies for cancer vaccine development | |
| Finn | Vaccines for cancer prevention: a practical and feasible approach to the cancer epidemic | |
| Kumai et al. | Cancer immunotherapy: moving forward with peptide T cell vaccines | |
| Obeid et al. | Vaccines, adjuvants, and dendritic cell activators—current status and future challenges | |
| JP2007524613A5 (cg-RX-API-DMAC7.html) | ||
| RU2013146324A (ru) | Иммунотерапевтические композиции на основе дрожжей с brachyury | |
| CA2267157A1 (en) | Cancer immunotherapy using tumor cells combined with mixed lymphocytes | |
| JP2004507231A5 (cg-RX-API-DMAC7.html) | ||
| ATE421533T1 (de) | Immunogene t-helfer epitope von menschlichen tumorantigenen und deren verwendung in immunotherapeutischen methoden | |
| Pawlik et al. | Malignant melanoma: current state of primary and adjuvant treatment | |
| JP2012021028A5 (cg-RX-API-DMAC7.html) | ||
| Pierini et al. | Trial watch: DNA-based vaccines for oncological indications | |
| JP2011041578A5 (cg-RX-API-DMAC7.html) | ||
| Bashir et al. | Immunotherapy regimens for metastatic colorectal carcinomas | |
| Baratta | Glioblastoma is ‘hot’for personalized vaccines | |
| He et al. | Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer | |
| McNeel | Therapeutic cancer vaccines: how much closer are we? | |
| WO2003085098A3 (en) | Identification of virulence associated regions rd1 and rd5 enabling the development of improved vaccines of m. bovis bcg and m. microti | |
| Ramlogan-Steel et al. | Lung cancer vaccines: current status and future prospects | |
| Ahmad et al. | DNA vaccination for prostate cancer, from preclinical to clinical trials-where we stand? | |
| EP4438053A3 (en) | An anaplastic lymphoma kinase (alk) cancer vaccine and methods of use | |
| Qu et al. | A Biomimetic Autophagosomes‐Based Nanovaccine Boosts Anticancer Immunity | |
| Fournier et al. | Randomized clinical studies of anti-tumor vaccination: state of the art in 2008 |